Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01125696
Other study ID # CDC-NCCDPHP-5877
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 2012
Est. completion date August 2018

Study information

Verified date July 2020
Source Centers for Disease Control and Prevention
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare a regimen of tenofovir/lamivudine/lopinavir-ritonavir to the WHO-recommended and locally practiced standard of care regimen consisting of zidovudine/lamivudine/lopinavir-ritonavir during the second and third trimesters of pregnancy in HIV and HBV co-infected women. This is a phase II study evaluating the safety of the test regimen in pregnant women and their newborns. While the study is not powered to examine efficacy, preliminary estimates of transmission of HIV and HBV to the infants and of the rate of resistance development will be obtained.


Description:

Great progress has been made in preventing mother-to-child transmission (MTCT) of HIV in resource-rich settings with the use of combination antiretroviral regimens during pregnancy and peripartum. In the resource-limited world simple inexpensive regimens administered peripartum, such as single dose nevirapine to mothers and infants, have been effective in reducing transmission but at the cost of development of resistance. Strategies that will allow women to preserve their antiretroviral options when they will need therapy for their own HIV disease and will improve efficacy are urgently needed. Moreover, co-infection with hepatitis B virus (HBV) is a problem for a substantial proportion of HIV-infected pregnant women. HIV alters the course of HBV disease by increasing levels of HBV DNA replication and thus risk of transmission to the newborn. HBV immunization in the infant with the first dose started soon after birth has decreased the bulk of such transmission, but the risk remains, particularly for mothers with HBe antigen positivity. Ideally an antiviral regimen administered during pregnancy with activity against both viruses would minimize transmission of both HIV and HBV to the infant.

The investigators propose to study a combination of tenofovir/lamivudine/lopinavir-ritonavir started between 14 and 28 weeks of pregnancy in HIV and HBV co-infected women. This regimen provides potent antiviral activity for prevention of MTCT. In addition, tenofovir and lamivudine both have activity against HBV, and could play a role in decreasing transmission of HBV to the infant. This regimen will be compared to the WHO-recommended and locally practiced standard of care, consisting of zidovudine/lamivudine/lopinavir-ritonavir, also starting at 14-28 weeks of pregnancy. This will be a phase II study evaluating the safety of the test regimen in pregnant women and their newborns, in particular renal, bone mineral density and hepatic toxicity (including hepatic flares post discontinuation of therapy). The study will recruit 80 pregnant women of at least 20 years of age in China and follow them and their infants for 12 months post-delivery. The investigators will recruit from prenatal clinics in some of the districts most heavily affected by HIV in the Guangxi province in China. China is selected for this study as it is hyperendemic for hepatitis B and has a rising HIV epidemic. Although not powered to examine efficacy, preliminary estimates of transmission of HIV and HBV to the infants and of the rate of resistance development will be obtained. The study will be done in collaboration with CDC-GAP China and the Chinese Ministry of Health-National Center for AIDS, which will coordinate recruitment, study visits and data collection through the local HIV/AIDS coordinators.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date August 2018
Est. primary completion date May 2018
Accepts healthy volunteers No
Gender Female
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Serologically-confirmed HIV and HBV infection

- Gestational age less than 28 weeks

- Willingness to participate in a clinical trial

- Age 20 years or over on the day of inclusion

- Willingness to return for follow-up visits and to allow infant participation in the trial

- Intent to remain in the clinic catchment area during the duration of the study

- No serious current complications of pregnancy

- No previous or current use of antiretrovirals including the HIVNET 012 regiment

- Hemoglobin over 8 g/dL

- Blood creatinine clearance greater than or equal to 60 mL/min estimated by the Cockroft-Gault formula for women

Exclusion Criteria:

- Age less than 20

- Pregnant woman refuses to sign the consent to participate

- Unwillingness to adhere to visit schedule or maintain adherence with medications

- Illnesses so severe as to likely require maternal hospitalization

- Intend to breastfeed

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tenofovir/lamivudine/lopinavir-ritonavir
Tenofovir/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4<350
Zidovudine/lamivudine/lopinavir-ritonavir
Zidovudine/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4<350

Locations

Country Name City State
China Liuzhou MCH Hospital Liuzhou Guangxi
China Guangxi MCH Hospital Nanning Guangxi

Sponsors (2)

Lead Sponsor Collaborator
Centers for Disease Control and Prevention National Center for AIDS/STD Control and Prevention, China CDC

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tenofovir Safety for mothers measured by incidence of serious adverse events (SAEs) SAEs will be defined using the DAIDS Toxicity Tables From baseline (14-28 weeks gestation) through 12 months postpartum
Primary Dual Energy X-ray absorptiometry (DXA) scans of bone mineral density Mothers will have DXA scan of hip and lumbar spine. Infants will have DXA scan of whole body and lumbar spine. from delivery through 6 months postpartum
Primary Maternal Tenofovir Pharmacokinetics Only for mothers on the active arm. 16 weeks gestation through delivery
Primary Infant Tenofovir Pharmacokinetics Only for infants on the active arm. one timepoint within 12 hours of delivery
Primary Tenofovir safety for infants measured by incidence of serious adverse events (SAEs) SAEs defined according to the DAIDS toxicity tables. from birth through 12 months of age
Secondary HBV viral load in mothers from baseline (14-28 weeks gestation) through delivery
Secondary Infant HIV transmission rate birth through 12 months
Secondary Infant HBV transmission rate birth through 12 months
Secondary Prevalence of HIV resistance mutations from baseline (14-28 weeks gestation) through 12 months postpartum
Secondary Prevalence of HBV resistance mutations from baseline (14-28 weeks gestation) through 12 months postpartum
See also
  Status Clinical Trial Phase
Recruiting NCT06162897 - Case Management Dyad N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT02528773 - Efficacy of ART to Interrupt HIV Transmission Networks
Active, not recruiting NCT05454839 - Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
Recruiting NCT05322629 - Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women N/A
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Active, not recruiting NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04519970 - Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) N/A
Completed NCT04124536 - Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women N/A
Recruiting NCT05599581 - Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT02758093 - Speed of Processing Training in Adults With HIV N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2